SavedAdd your journal

Journals / Eurasian Journal of Medical Investigation / 2019 / Cilt: 3 - Sayı: 1

Idiopathic Hypogonadotropic Hypogonadism: Erythrocyte Indices in Naive Male Patients

Zafer PEKKOLAY
Pages
74–76
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Hb levels, Htc levels and MCV levels of the patient group were lower and statistically significantthan the control group.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The aim of this study was to determine the erythrocyte indices in patients with naive male idiopathic hypogonadotropichypogonadism.Methods: In our retrospective cross-sectional study, patients who were admitted to the university hospital adult endocrinologyoutpatient clinic naive male idiopathic hypogonadotropic hypogonadism between 1 January 2010 and 30September 2018 were included.
📊
Key Findings & Data:The patient group consisted of naive male patients diagnosed as hypogonadotropichypogonadism who had no anatomic or functional hypothalamo-hypophyseal disease between the ages of 18-40.Healthy men in the same age range were taken as control group.
💡
Conclusion & Impact:Hb levels, Htc levels and MCV levels of the patient group were lower and statistically significantthan the control group.
🔬Design:Research Article
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: The aim of this study was to determine the erythrocyte indices in patients with naive male idiopathic hypogonadotropichypogonadism.Methods: In our retrospective cross-sectional study, patients who were admitted to the university hospital adult endocrinologyoutpatient clinic naive male idiopathic hypogonadotropic hypogonadism between 1 January 2010 and 30September 2018 were included. The patient group consisted of naive male patients diagnosed as hypogonadotropichypogonadism who had no anatomic or functional hypothalamo-hypophyseal disease between the ages of 18-40.Healthy men in the same age range were taken as control group. In patients with naive idiopathic hypogonadotropichypogonadism, LH, FSH and Testosteron values in serum were measured. All patients erythrocyte indices(Hb, Htc, MCV,RDW) and platelets were measured. Student’s t test was used to compare groups.Results: The study included 145 male patients (78 patients and 67 control group). There was no difference in agebetween the groups (p>0.05). Hb levels, Htc levels and MCV levels of the patient group were lower and statistically significantthan the control group. Respectively (p

🔖

Cite This Article

PEKKOLAY, Z. (2022). Idiopathic Hypogonadotropic Hypogonadism: Erythrocyte Indices in Naive Male Patients. Eurasian Journal of Medical Investigation, Cilt: 3 - Sayı: 1, 74–76. https://ajindex.com/articles/508761

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Boehm U, Bouloux PM, Dattani MT, de Roux N, Dodé C, Dunkel L, et al. Consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadismpathogenesis, diagnosis and treatment. Nat Rev Endocrinol 2015;11:547–64
  2. Bianco SD, Kaiser UB. The genetic and molecular basis of idiopathic hypogonadotropic hypogonadism. Nat Rev Endocrinol 2009;569–76
  3. Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, et al. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab 2008;93:914–9
  4. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018;103:1715–44
  5. Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Boloña ER, Sideras K, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebocontrolled trials. Mayo Clin Proc 2007;82:29–39
  6. Shahani S, Braga-Basaria M, Maggio M, Basaria S. Androgens and erythropoiesis: past and present. J Endocrinol Invest 2009;32:704–16
  7. Guo W, Bachman E, Li M, et al. Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells. Aging Cell 2013;12:280–91
  8. Andrews NC. Disorders of iron metabolism. N Engl J Med 1999;23;341:1986–95
  9. Ohlander SJ, Varghese B, Pastuszak AW. Erythrocytosis Following Testosterone Therapy. Sex Med Rev 2018;6:77–85
  10. Bachman E, Travison TG, Basaria S, Davda MN, Guo W, Li M, et al. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/ hemoglobin set point. J Gerontol A Biol Sci Med Sci 2014;69:725–35
  11. Lenzi A, Balercia G, Bellastella A, Colao A, Fabbri A, Foresta C, et al. Epidemiology, diagnosis, and treatment of male hypogonadotropic hypogonadism. J Endocrinol Investig 2009;32:934–8
  12. Paustian L, Chao MM, Hanenberg H, Schindler D, Neitzel H, Kratz CP, Ebell W. Androgen therapy in Fanconi anemia: A retrospective analysis of 30 years in Germany. Pediatr Hematol Oncol 2016;33:5–12
  13. Roy CN, Snyder PJ, Stephens-Shields AJ, Artz AS, Bhasin S, Cohen HJ, et al. Association of Testosterone Levels With Anemia in Older Men: A Controlled Clinical Trial. JAMA Intern Med 2017;177:480–90
  14. Hicks BM, Klil-Drori AJ, Yin H, Campeau L, Azoulay L. Androgen Deprivation Therapy and the Risk of A